BSG and hepatocellular carcinoma: For instance, an anti-CD147-conjugated PLD (anti-CD147 ILs-DOX) was developed in 2018 to target the CD147, an overexpressed glycoprotein on the surface of hepatocellular carcinoma (HCC) cells that potentiates tumor progression.